• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

    2/9/24 8:50:22 AM ET
    $GMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMTX alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 DISC MEDICINE INC COMMON STOCK Cusip #254604101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #254604101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,166,748 Item 6: 0 Item 7: 2,166,819 Item 8: 0 Item 9: 2,166,819 Item 11: 8.975% Item 12: HC Cusip #254604101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,166,819 Item 8: 0 Item 9: 2,166,819 Item 11: 8.975% Item 12: IN Item 1(a). Name of Issuer: DISC MEDICINE INC Item 1(b). Address of Issuer's Principal Executive Offices: 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE, MA 02139 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 254604101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,166,819 (b) Percent of Class: 8.975% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,166,819 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of DISC MEDICINE INC. The interest of Select Biotechnology Portfolio, in the COMMON STOCK of DISC MEDICINE INC, amounted to 1,765,397 shares or 7.313% of the total outstanding COMMON STOCK at December 29, 2023. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of DISC MEDICINE INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $GMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMTX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $2.00Buy → Neutral
    HC Wainwright & Co.
    3/3/2022$10.00 → $2.00Outperform → Market Perform
    SVB Leerink
    3/1/2022$23.00 → $1.50Buy → Hold
    Jefferies
    1/24/2022$15.00 → $10.00Outperform
    SVB Leerink
    12/20/2021$25.00 → $15.00Outperform
    SVB Leerink
    12/15/2021$20.00Buy
    HC Wainwright & Co.
    10/6/2021$20.00 → $18.00Buy
    Goldman Sachs
    More analyst ratings

    $GMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

      WATERTOWN, Mass., Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the U.S. Food and Drug Administration ("FDA") granted Orphan Drug Designation to bitopertin for the treatment of erythropoietic protoporphyria ("EPP"). Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 ("GlyT1") designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX ("PPIX"), the toxic metabolite that causes dise

      12/27/22 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      WATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients living with serious hematologic diseases, presented five posters spanning several of its hematology programs at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, LA. "Disc Medicine continues to make considerable progress towards the development of potentially first-in-class therapeutic candidates for hematologic disorders," said John

      12/13/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, LA on December 10-13, 2022.  "We are pleased to have five abstracts selected for presentat

      11/3/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    SEC Filings

    See more
    • Gemini Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Disc Medicine, Inc. (0001816736) (Filer)

      2/7/24 8:10:55 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:47:19 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:44:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gemini Therapeutics downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Gemini Therapeutics from Buy to Neutral and set a new price target of $2.00 from $5.00 previously

      3/11/22 6:36:28 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Gemini Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $10.00 previously

      3/3/22 6:29:25 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Gemini Therapeutics from Buy to Hold and set a new price target of $1.50 from $23.00 previously

      3/1/22 6:13:52 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Franchi Jean M. was granted 36,666 shares (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:37:53 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Franchi Jean M.

      3 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:33:28 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bitterman Kevin sold $6,934,125 worth of shares (102,500 units at $67.65) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      1/25/24 4:33:04 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Gemini Therapeutics Provides Corporate Update

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order

      2/28/22 8:30:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company's Board of Directors. "I am pleased to welcome Georges to Gemini's Board of Directors during this important time in our Company's maturation, as we advance our lead program into the next stages of clinical development," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "Georges' broad management experience and proven track record of commercial and product development success wi

      5/3/21 7:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately. "We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus deca

      4/12/21 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/14/24 4:08:06 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/13/24 6:51:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/9/24 8:50:22 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care